Translational Psychophysiology and Assessment Laboratory (T-PAL)

  1. Sansone SM, Schneider A, Bickel E, Berry-Kravis E, Prescott C, & Hessl D (2014).  Improving IQ measurement in intellectual disabilities using true deviation from population norms.  Journal of Neurodevelopmental Disorders 6(16), 1-14.
  2. McCormick C, Hessl D, Macari SL, Ozonoff S, Green C, Rogers SJ (2014). Electrodermal and behavioral responses of children with autism spectrum disorders to sensory and repetitive stimuli.  Autism Research 7(4), 468-480.
  3. Ballinger EC, Cordeiro L, Chavez AD, Hagerman RJ, & Hessl D (2014).  Emotion potentiated startle in fragile X syndrome.  Journal of Autism and Developmental Disabilities 44(10), 2536-2546.
  4. Cohen S, Masyn K, Mastergeorge A, & Hessl D (2013).  Psychophysiological responses to emotional stimuli in children and adolescents with autism and fragile X syndrome. Journal of Clinical Child and Adolescent Psychology. PMID: 24156344.
  5. Schneider A, Leigh MJ, Adams P, Nanakul R, Chechi T, Olichney J, Hagerman RJ, & Hessl D (2013). Electrocortical changes associated with minocycline treatment in fragile X syndrome.  Journal of Psychopharmacology, 27(10), 965-963. PMID: 23981511.
  6. Berry-Kravis E, Hessl D, Abbeduto L, Reiss AL, Beckel-Michener A, & Urv TK (2013). Outcome measures for clinical trials in fragile X syndrome. Journal of Developmental and Behavioral Pediatrics, 34(7) 508-522.  PMID: 24042082.
  7. Russo-Ponsaran N, Yesensky J, Hessl D, & Berry-Kravis E (In press).  Feasibility, reproducibility, and clinical validity of the Pediatric Anxiety Rating Scale – Revised for fragile X syndrome.  American Journal on Intellectual and Developmental Disabilities 119(1), 1-16.
  8. Schneider A, Seritan A, Tassone F, Rivera S, Hagerman RJ, & Hessl D (2013).  Psychiatric features in high-functioning adult brothers with fragile X spectrum disorders.  The Primary Care Companion for CNS Disorders, 15(2).
  9. Leigh MJS, Nguyen DV, Mu Y, Winarni TI, Schneider A, Chechi T, Polussa J, Doucet P, Tassone F, Rivera SM, Hessl D, & Hagerman RJ (2013). A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile X syndrome. Journal of Developmental and Behavioral Pediatrics, 34(3), 147-155. PMID: 23572165
  10. Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, Mu Y, Nguyen DM, Gonzalez-Heydrich J, Wang PP, Carpenter RL, Bear MF, & Hagerman RJ (2012). Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A randomized, controlled, Phase 2 trial. Science Translational Medicine, 4(152): 152ra127. PMID: 22993294
  11. Knox A, Schneider A, Abucayan F, Hervey C, Tran C, Hessl D & Berry-Kravis E (2012).  Feasibility, Reliability, and Clinical Validity of the Tests of Attentional Performance for Children (KiTAP) in Fragile X Syndrome (FXS).  Journal of Neurodevelopmental Disorders 4: 2. PMID: 22958782)
  12. Sansone SM, Widaman KF, Hall SS, Reiss AL, Lightbody A, Kaufmann WE, Berry-Kravis E, Lachiewicz A, Brown EC, & Hessl D (2011).  Psychometric study of the Aberrant Behavior Checklist in fragile X syndrome and implications for targeted treatment.  Journal of Autism and Developmental Disorders 42(7), 1377-1392. PMID: 21972117
  13. Hessl D, Wang JM, Schneider A, Koldewyn K, Le L, Iwahashi C, Tassone F, Hagerman PJ, & Rivera SM (2011).  Deficient FMRP underlies amygdala dysfunction in carriers of the fragile X premutation.  Biological Psychiatry, 70(9), 859-865. PMID: 21783174
  14. Farzin F, Scaggs F, Hervey C, Berry-Kravis E, & Hessl D (2011).  Reliability of eye tracking and pupillometry measures in individuals with fragile X syndrome.  Journal of Autism and Developmental Disorders, 41(11), 1515-1522. PMID: 21267642
  15. Cordeiro, L., Ballinger, E., Hagerman RJ, & Hessl D (2011). Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: Prevalence and characterization.  Journal of Neurodevelopmental Disorders 3, 57-67. PMID: 21475730
  16. Schneider, A., Ballinger, E., Chavez, A., Tassone F, Hagerman RJ, & Hessl D (2010).  Prepulse inhibition in patients with fragile X-associated tremor ataxia syndrome.  Neurobiology of Aging, 33(6), 1045-1053.  PMID: 20961665
  17. Yuhas J, Cordeiro L, Tassone F, Ballinger L, Schneider A, Long JM, Ornitz EM, & Hessl D (2010).  Sensorimotor gating in idiopathic autism and autism associated with fragile X syndrome. Journal of Autism and Developmental Disorders, 41(2), 248-253.  PMID: 20521090
  18. Farzin F, Rivera SM, & Hessl D (2009).  Face processing in individuals with fragile X syndrome: An eye tracking study.  Journal of Autism and Developmental Disorders, 39(6) 946-952.
  19. Berry-Kravis E, Hessl D, Coffey S, Hervey C, Schneider A, Yuhas J, Hutchinson J, Snape M, Tranfaglia M, Nguyen DV, & Hagerman RJ (2009).  A pilot open-label singe-dose trial of Fenobam in adults with fragile X syndrome.  Journal of Medical Genetics, 46(4) 266-271. PMID: 19126569
  20. Hessl D, Nguyen DV, Green C, Chavez A, Tassone F, Hagerman RJ, Senturk D, Schneider A, Lightbody A, Reiss AL & Hall S (2009). A solution to limitations of cognitive testing in children with intellectual disabilities: The case of fragile X syndrome.  Journal of Neurodevelopmental Disorders, 1, 33-45. PMID: 19865612
  21. Hessl D, Cordeiro L, Yuhas J, Campbell A, Ornitz E, Berry-Kravis E, Chruscinski E, Hervey C, Long JM, & Hagerman RJ (2009).  Prepulse inhibition in fragile X syndrome: Feasibility, reliability and implications for treatment.  American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 150B(4) 545-553
  22. Hessl D, Tassone F, Cordeiro L, Koldewyn K, McCormick C, Green C, Wegelin J, Yuhas J, & Hagerman RJ (2008).  Aggression and stereotypic behavior in males with fragile X syndrome: Moderating secondary genes in a “single gene” disorder.  Journal of Autism and Developmental Disorders 38(1), 184-189.
  23. Hessl D, Rivera SR, Koldewyn K, Cordeiro L, Adams J, Tassone F, Hagerman PJ, & Hagerman RJ (2007).  Amygdala dysfunction in men with the fragile X premutation.  Brain 130(2), 404-416.
  24. Hessl D, Tassone F, Loesch, DZ, Berry-Kravis E, Leehey M, Gane LW, Barbato I, Rice C, Gould E, Hall DA, Grigsby J, Wegelin JA, Harris S, Lewin F, Weinberg D, Hagerman PJ & Hagerman RJ (2005).  Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation.  American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 139B: 115-121.

-back to top